SEARCH

SEARCH BY CITATION

Keywords:

  • hepatitis C;
  • peginterferon alfa-2a (40KD);
  • pharmacokinetics;
  • population;
  • ribavirin

Aim

A population pharmacokinetic analysis was performed using plasma concentration data (n = 7025) from 380 patients to examine the relationship between ribavirin dose and its pharmacokinetics.

Methods

Ribavirin pharmacokinetics were described by a three-compartment model with sequential zero-order and a first-order absorption processes. Interoccasion variability and food effects were included.

Results

Lean body weight (range 41–91 kg) was the only covariate with a clinically significant influence on ribavirin pharmacokinetics, affecting clearance (15.3–23.9 l h−1) and the volume of the larger peripheral compartment.

Conclusion

The model provided a good description of the available data, confirmed by accurate estimates of parameter values and low residual variability (17%).